Case Note & Summary
The Supreme Court addressed a series of civil appeals concerning the applicability of excise duty exemptions for Intravenous Fluids manufactured by the respondent company. The core issue revolved around whether these fluids, which included additional therapeutic substances, fell under the exemption provided by Notification No.3/2001. The respondents had previously benefited from Notification No.6/2000, which was amended to include an exemption for Intravenous Fluids. However, Notification No.3/2001 introduced a more restrictive definition, limiting the exemption to fluids used solely for sugar, electrolyte, or fluid replenishment. The court noted that the Department issued show cause notices alleging that the addition of therapeutic items to the fluids disqualified them from exemption. The court highlighted that the 2001-2002 Budget included clarifications that further restricted the definition of exempt IV Fluids. The Tribunal had not adequately addressed these clarifications, prompting the court to remand the matter for fresh consideration. Additionally, the court pointed out that the labeling of the fluids as Schedule-H drugs due to their therapeutic value needed examination, as this could impact their exemption status. The court emphasized that exemption notifications must be interpreted strictly and placed the burden of proof on the assessee to demonstrate compliance with the exemption criteria. Ultimately, the court allowed the Department's appeals, set aside the impugned judgment, and remitted the matters to the Tribunal for a thorough review in accordance with the law, with no order as to costs.
Headnote
A) Excise Law - Exemption Notification - Definition of Intravenous Fluids - Notification No.3/2001 - The court examined whether the definition of 'IV Fluids' under Notification No.3/2001, which restricts exemption to fluids used for sugar, electrolyte or fluid replenishment, was applicable to products with added therapeutic value. The matter was remitted to the Tribunal for a detailed examination of the 2001-2002 Budget provisions and their implications on the exemption claim (Paras 1-2). B) Drugs and Cosmetics - Schedule-H Drug - Therapeutic Value of IV Fluids - The court noted that the addition of certain items to IV Fluids could classify them as Schedule-H drugs, thus affecting their exemption status. The Tribunal was directed to consider this aspect and determine if further evidence was necessary (Paras 2-3).
Issue of Consideration
Whether Intravenous Fluids with therapeutic value are covered under Exemption Notification No.3/2001.
Final Decision
The Supreme Court allowed the Department's appeals, set aside the impugned judgment, and remitted the matters to the Tribunal for fresh consideration in accordance with law, with no order as to costs.
Law Points
- Excise duty exemption
- therapeutic value
- Notification No.3/2001
- Schedule-H Drug
- burden of proof
